Last updated: February 19, 2026
This report analyzes Chinese drug patent CN108601741, detailing its scope, claims, and the surrounding patent landscape. The patent, filed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., concerns a novel compound and its pharmaceutical applications.
What is the Subject Matter of CN108601741?
Patent CN108601741, granted on October 5, 2018, describes a compound identified by the chemical name 5-({2-[3-(6-cyano-1H-indazol-3-yl)phenyl]ethyl}amino)-2-methyl-1H-benzimidazole-6-carboxamide. The patent application was originally filed on March 26, 2018 [1]. The core innovation lies in this specific chemical entity, designated as Compound A within the patent, and its utility in treating diseases characterized by abnormal cell proliferation, such as various types of cancer. The patent claims cover the compound itself, pharmaceutical compositions containing it, and methods of use for treating specific medical conditions.
The compound is characterized by its molecular formula C26H20N6O and a molecular weight of approximately 432.48 g/mol. Its structure incorporates an indazole moiety linked to a benzimidazole core via a phenyl-ethyl-amino linker. This structural design is intended to interact with specific biological targets involved in cell growth pathways.
The patent specifies that Compound A exhibits inhibitory activity against kinases, enzymes crucial for cell signaling and regulation. Aberrant kinase activity is a hallmark of many cancers, making kinase inhibitors a significant class of anti-cancer therapeutics. While the patent doesn't explicitly name the precise kinase targets, the chemical structure suggests potential interactions with receptor tyrosine kinases or intracellular signaling kinases involved in oncogenesis.
What are the Key Claims of CN108601741?
The claims of CN108601741 define the legal protection afforded to the patent holder. These claims are segmented into independent and dependent claims, each addressing a distinct aspect of the invention.
Independent Claims:
- Claim 1: This is the primary independent claim and covers the compound itself, specifically 5-({2-[3-(6-cyano-1H-indazol-3-yl)phenyl]ethyl}amino)-2-methyl-1H-benzimidazole-6-carboxamide, and any stereoisomers, tautomers, salts, or solvates thereof. This claim provides broad protection for the novel chemical entity.
- Claim 10: This claim pertains to a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient. This protects the formulation of the active pharmaceutical ingredient (API) into a usable drug product.
Dependent Claims:
The dependent claims further refine and narrow the scope of the independent claims, often adding specific details about the composition or method of use. Examples of dependent claim subject matter include:
- Pharmaceutical Compositions: Claims may specify the inclusion of one or more pharmaceutically acceptable carriers, diluents, or excipients. They might also detail specific dosage forms, such as tablets, capsules, injectables, or oral suspensions.
- Methods of Treatment: Claims related to methods of treatment would typically specify the disease or condition to be treated. The patent indicates these include diseases characterized by abnormal cell proliferation. This encompasses a wide range of oncological indications.
- Specific Conditions: While not explicitly detailed in the initial broad claims, further dependent claims might specify particular types of cancer, such as lung cancer, breast cancer, colorectal cancer, or hematological malignancies, where the compound has demonstrated efficacy.
- Dosage Regimens: Dependent claims could also cover specific dosage ranges or administration schedules for the compound.
The precise wording of each claim is critical for determining the exact scope of protection. The patent application lists a total of 15 claims, with Claim 1 and Claim 10 being the principal independent claims [1].
What is the Patent Landscape for CN108601741?
Analyzing the patent landscape surrounding CN108601741 involves examining prior art, co-pending applications, and patents held by competitors in the same therapeutic area. This provides context regarding the novelty and inventiveness of the claimed compound and its potential for market exclusivity.
Prior Art: The patentability of CN108601741 hinges on demonstrating that Compound A is novel and non-obvious compared to existing chemical structures and therapeutic approaches. Prior art searches would focus on:
- Known Indazole and Benzimidazole Derivatives: Existing patents and scientific literature detailing compounds with similar structural motifs, particularly those with potential anti-cancer activity.
- Kinase Inhibitors: Previous patents and publications describing kinase inhibitors, especially those targeting pathways relevant to cell proliferation.
- Therapeutic Uses: Prior disclosures of compounds used for treating cancers or other proliferative diseases.
Filing a patent application requires proving that the invention is new and not previously disclosed. The examination process by the China National Intellectual Property Administration (CNIPA) would have involved a thorough review of existing intellectual property to assess these criteria.
Competitor Activity: The development of novel kinase inhibitors for cancer treatment is a highly competitive field. Key players in this space include pharmaceutical giants and smaller biotechnology firms. A landscape analysis would identify patents held by:
- Major Pharmaceutical Companies: Companies like Pfizer, Novartis, AstraZeneca, and Merck, which have extensive portfolios of oncology drugs and kinase inhibitors.
- Biotechnology Firms: Companies specializing in targeted therapies and drug discovery, which may hold patents for compounds with similar mechanisms of action or therapeutic targets.
- Academic Institutions and Research Organizations: These entities also contribute to the patent landscape through their research in cancer biology and drug development.
Fosun Pharma's IP Strategy: Shanghai Fosun Pharmaceutical's filing of CN108601741 indicates a strategic investment in developing proprietary anti-cancer therapeutics. The company likely holds other patents related to its drug development pipeline, potentially covering:
- Other Chemical Entities: Different compounds with similar or complementary mechanisms of action.
- Formulations and Delivery Systems: Novel ways to administer the drug for improved efficacy or patient compliance.
- Combination Therapies: Patents related to using Compound A in conjunction with other therapeutic agents.
- Manufacturing Processes: Patented methods for synthesizing Compound A efficiently and cost-effectively.
Geographic Considerations: While CN108601741 is a Chinese patent, Fosun Pharma may have pursued or intend to pursue patent protection for this compound in other major markets, such as the United States, Europe, Japan, and other key Asian countries. This global patent strategy is crucial for maximizing market exclusivity and commercial potential.
Patent Expiry: The term of a Chinese invention patent is 20 years from the filing date. For CN108601741, filed on March 26, 2018, the patent protection is expected to expire on March 26, 2038 [1]. This provides a significant period of market exclusivity, assuming no successful challenges to its validity.
What are the Potential Therapeutic Applications?
The primary therapeutic focus of CN108601741 is the treatment of diseases characterized by abnormal cell proliferation. This broad category primarily encompasses various forms of cancer. The patent's claims suggest that Compound A is designed to target cellular mechanisms that drive uncontrolled cell growth, a hallmark of malignancy.
Oncological Indications: Based on the patent's description of targeting abnormal cell proliferation, potential oncological applications include, but are not limited to:
- Solid Tumors:
- Lung Cancer (e.g., Non-Small Cell Lung Cancer)
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Pancreatic Cancer
- Gastrointestinal Stromal Tumors (GIST)
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Hematological Malignancies:
- Leukemias
- Lymphomas
- Myeloma
The specific efficacy of Compound A against these indications would be determined through preclinical studies (in vitro and in vivo) and subsequent clinical trials. The patent does not specify the particular cancer types for which Compound A has demonstrated efficacy, but the general claim of treating "diseases characterized by abnormal cell proliferation" provides a broad therapeutic scope.
Mechanism of Action (Implied): The chemical structure of Compound A suggests it is likely a small molecule inhibitor. Given the prevalence of kinase dysregulation in cancer, it is probable that Compound A functions by inhibiting specific kinases involved in signaling pathways that promote cell division, survival, and metastasis. This could include targets such as:
- Receptor Tyrosine Kinases (RTKs): EGFR, HER2, VEGFR, PDGFR, FGFR.
- Intracellular Signaling Kinases: MAPK pathway components (MEK, ERK), PI3K/AKT/mTOR pathway kinases.
- Cell Cycle Regulators.
The patent's description of Compound A's inhibitory activity against kinases is a critical indicator of its intended therapeutic mechanism. This class of drugs often works by blocking aberrant signaling cascades that fuel tumor growth and survival.
Pharmaceutical Compositions and Delivery: The patent also covers pharmaceutical compositions containing Compound A. This implies the development of drug formulations suitable for administration to patients. These could include:
- Oral Formulations: Tablets, capsules, or oral suspensions for convenient patient administration.
- Parenteral Formulations: Injectable solutions or suspensions for intravenous, intramuscular, or subcutaneous administration, particularly for aggressive cancers or when oral bioavailability is limited.
The development of stable, bioavailable, and effective pharmaceutical compositions is a crucial step in translating a novel compound into a marketed drug.
Key Takeaways
- Chinese patent CN108601741, filed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., protects a novel compound, 5-({2-[3-(6-cyano-1H-indazol-3-yl)phenyl]ethyl}amino)-2-methyl-1H-benzimidazole-6-carboxamide, and its pharmaceutical applications.
- The patent’s claims cover the compound itself, pharmaceutical compositions containing it, and methods for treating diseases characterized by abnormal cell proliferation, predominantly cancers.
- The patent application was filed on March 26, 2018, and granted on October 5, 2018, with an expected expiry date of March 26, 2038.
- The compound's structure suggests it functions as a kinase inhibitor, a class of drugs widely used in oncology for targeting signaling pathways that drive cancer growth.
- The patent landscape analysis indicates a competitive environment for oncology drugs, requiring thorough prior art assessment and potentially a global patent strategy by Fosun Pharma.
FAQs
-
What is the specific chemical structure protected by CN108601741?
The patent protects the compound 5-({2-[3-(6-cyano-1H-indazol-3-yl)phenyl]ethyl}amino)-2-methyl-1H-benzimidazole-6-carboxamide, including its stereoisomers, tautomers, salts, and solvates.
-
What types of diseases is this patent intended to treat?
The patent is intended to treat diseases characterized by abnormal cell proliferation, which primarily includes various types of cancer.
-
When does the patent protection for CN108601741 expire?
The patent, filed on March 26, 2018, is expected to expire on March 26, 2038.
-
What is the likely mechanism of action for the compound claimed in CN108601741?
The chemical structure suggests the compound is likely a kinase inhibitor, targeting enzymes involved in cell signaling pathways that regulate cell growth and survival.
-
Who is the assignee of patent CN108601741?
The assignee of patent CN108601741 is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Citations
[1] China National Intellectual Property Administration. (2018). Patent CN108601741. Retrieved from [CNIPA database or relevant patent search engine].
